Utilization of stable isotope labeling to facilitate the identification of polar metabolites of KAF156, an antimalarial agent

Su-Er W. Huskey, Ry R. Forseth, Hongmei Li, Zhigang Jian, Alexandre Catoire, Jin Zhang, Tapan Ray, Handan He, Jimmy Flarakos, and James B. Mangold

Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, East Hanover, NJ
Running Title

Identification of polar metabolites of KAF156

Corresponding Author

Su-Er Wu Huskey

Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, NJ 07936-1080

Telephone 862-778-0940

Fax 973-781-5023

E-mail Address Su.huskey@novartis.com

Text page 24

Table 1

Figures 10

References 24

Words in Abstract 260

Words in Introduction 717

Words in Discussion 1310
Abbreviations:

KAF156, 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl)amino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone; ADME, absorption, distribution, metabolism and excretion; AUC, area under concentration-time curve; C_{max}, the observed maximum concentration in blood or plasma following drug administration; DQF-COSY, double quantum filter correlation spectroscopy; FPOAA, 2-(4-fluorophenyl)-2-oxoacetic acid; HPLC, high performance liquid chromatography; i.v., intravenous; LC-MS/MS, liquid chromatography-tandem mass spectrometry; LSC, liquid scintillation counting; μCi, microcurie; PK, pharmacokinetics; p.o., oral; QC, quality control; ROESY, rotational frame nuclear Overhauser effect spectroscopy; t_{1/2}, the terminal elimination half-life; t_{max}, the time to reach the maximum concentration after drug administration.
Abstract

Identification of polar metabolites of drug candidates during development is often challenging. Several prominent polar metabolites of [14C]KAF156, an antimalarial agent, were detected in rat urine from an ADME study, but could not be characterized by LC-MS/MS due to low ionization efficiency. In such instances a strategy often chosen by investigators is to use a radiolabeled compound with high specific activity, having an isotopic mass ratio (i.e., [12C]/[14C]) and mass difference that serves as the basis for a mass filter using accurate mass spectrometry. Unfortunately, [14C]KAF156-1 was uniformly labeled (n=1-6) with the mass ratio of ~0.1. This ratio was insufficient to be useful as a mass filter despite the high specific activity (120 μCi/mg).

At this stage in development, stable isotope labeled [13C6]KAF156-1 was available as the internal standard for the quantification of KAF156. We were thus able to design an oral dose, as a mixture of [14C]KAF156-1 (specific activity 3.65 μCi/mg) and [13C6]KAF156-1 with a mass ratio of [12C]/[13C6] as 0.9 and the mass difference as 6.0202. Using this mass filter strategy, four polar metabolites were successfully identified in rat urine. Subsequently, using a similar dual labeling approach, [14C]KAF156-2 and [13C2]KAF156-2 were synthesized to allow the detection of any putative polar metabolites which may have lost labeling during biotransformations using the previous [14C]KAF156-1. Three polar metabolites were thereby identified and M43, a less polar metabolite, was proposed as the key intermediate metabolite leading to the formation of a total of seven polar metabolites. Overall this dual labeling approach proved practical and valuable for the identification of polar metabolites by LC-MS/MS.
Introduction

Malaria affects approximately 200 million people worldwide every year, particularly among young children in developing countries. Recent reports of drug resistant strains to artemisinin, a first-line treatment for uncomplicated P. falciparum malaria, in Southeast Asia cause concerns for health authorities and the pharmaceutical industry (Hague et al., 2013; Na-Bangchang et al., 2013; Witkowski et al., 2013). Increased efforts have been undertaken to understand the mechanism of resistance toward the current artemisinin containing combination therapy (Carter et al., 2015; Holt et al., 2015).

Several antimalarial compounds are currently in phase II development and their structures are diverse as they are either from existing or new chemical scaffolds, targeting different mechanisms of action (Held et al., 2015). Furthermore, other approaches including vaccination and next generation antimalarial drug candidates have been evaluated for efficacy and safety for malaria prophylaxis treatment (Amet et al., 2013; Diagana TT, 2015; Nahrendorf et al., 2015; Sagara et al., 2014 and Teneza-Mora et al., 2015). Preventative treatment in children is expected to potentially avert 11 million cases and 50,000 deaths every year.

KAF156 (Nagle et al., 2012 and Wu et al., 2011; Figure 1) is a first-in-class, antimalarial compound designed to eradicate both blood-stage and liver-stage malaria parasites (Diagana TT, 2015; Kuhlen et al., 2014; Meister et al., 2011). In clinical trials, KAF156 has been shown to be safe and well tolerated in healthy volunteers (Leong et al., 2014). In the proof of concept trial, a single dose of KAF156 was administered to healthy volunteers either prior to or after exposure to Plasmodium falciparum infected mosquitoes. In both cases, KAF156 was equally effective and prevented malaria in every volunteer receiving the drug. KAF156 has the potential to be used
safely for malaria prophylaxis for travelers to endemic countries, deployed soldiers and children living in high risk regions.

We conducted rat ADME and across species in vitro metabolism studies in preparation for the above clinical investigation during the development of KAF156. Several metabolites were identified in rat plasma and feces by LC-MS/MS analysis; however, four prominent polar metabolites of KAF156, accounting for ~24-37% of the i.v. and p.o. dose, were detected by radioactivity in rat urine but could not be characterized by LC-MS/MS. It was very challenging to identify these polar metabolites due to their low ionization efficiency and suspected low molecular weights.

For the identification of metabolites in biological matrices by accurate mass spectrometry, one of the strategies routinely chosen by investigators is the use of radiolabeled compound with high specific activity, where the isotopic mass ratio (e.g. $^{12}\text{C} : ^{14}\text{C} = 1:0.3$) is adequate to serve as a mass filter (Ma et al., 2006; Zhang and Mitra, 2012). However, the available $^{14}\text{C}$KAF156-1 (Figure 1) was uniformly labeled (n=1-6) with the mean $^{12}\text{C}/^{14}\text{C}$ mass ratio of ~0.1, which was too low to be suitable as a mass filter, even though the specific activity was reasonably high (120 $\mu$Ci/mg). At this stage in development, stable isotope labeled compound ($^{13}\text{C}_6$KAF156-1) was available for use as an internal standard for the quantification of KAF156 in toxicology studies under good laboratory practice (GLP). We took advantage of the availability of this internal standard and designed an oral dose as a mixture of $^{14}\text{C}$KAF156-1 (specific activity 3.65 $\mu$Ci/mg) and $^{13}\text{C}_6$KAF156-1 with the mass ratio of $^{12}\text{C}/^{13}\text{C}_6$ as 0.9 and mass difference of 6.0202. In principle, following dosing of $^{12}\text{C}$KAF156 and $^{13}\text{C}_6$KAF156-1 to rats, any metabolites containing fluoroaniline portion would be generated as isotopic pairs in vivo, sharing
the signature mass ratio of 0.9 and mass difference of 6.0202, thereby rendering them easily identified using a defined mass filter by accurate mass spectrometry.

Subsequently, an alternative tracer ([14C]KAF156-2) was prepared to allow detection of any putative polar metabolites which may have lost radiolabeling and were not detected using [14C]KAF156-1 (Figure 1). Using a similar dual labeling strategy, [13C2]KAF156-2 was synthesized and combined with [14C]KAF156-2 in the oral dose to facilitate the identification of polar metabolites.

In this article, we describe the strategies and approaches used in the identification of a total of seven polar metabolites of KAF156. We also describe two unexpected hurdles we encountered during our metabolite investigations and describe solutions to overcome the challenges. Overall, the dual labeling approaches have proven to be valuable for the identification of polar metabolites with low molecular weights and low ionization efficiency.
Materials and Methods

Chemicals
KAF156 (Nagle et al., 2012 and Wu et al., 2011; Figure 1) was synthesized by Novartis Institute for Tropical Diseases. [14C]KAF156-1, [14C]KAF156-2, [13C6]KAF156-1, and [13C2]KAF156-2 were prepared by Novartis Isotope laboratories and radiochemical purity was >99%.

4-fluoromandelic acid, fluoroaniline, hydroxyphenylacetamide, acetonitrile, methanol, ammonium formate, and formic acid were from Sigma-Aldrich (St. Louis, MO). OPTI-FLUOR liquid scintillant was from Packard (Downers Grove, IL). Control blank plasma samples from rat were purchased from Bioreclamation (Hicksville, NY).

Animals
Male Wistar Hannover rats (~250-320 g, ~8 week, n=24) were from Harlan Laboratories (Somerville, NJ). Catheters were surgically implanted into the carotid artery and/or jugular vein of rats by the vendor (only one catheter was implanted into carotid artery for blood collection from rats receiving oral dose). All rats were housed individually in metabolism cages (Culex Autosampler, BAS, Indianapolis, IN) in a temperature and humidity controlled room with free access to food and water (food was withheld until 4 h post-dose).

Dose administration
All doses were administered based on the individual animal body weights on the day of dosing. As shown in Figure 1, [14C]KAF156-1 and [14C]KAF156-2 with different 14C labeling positions and two stable isotope labeled forms of KAF156 ([13C6]KAF156-1 and [13C2]KAF156-2) were synthesized and used for the dose preparations. A total of 4 subgroups of rats were dosed either i.v. or p.o.. For mass balance studies, [14C]KAF156-1 (specific activity 66 μCi/mg at 3 mg/kg...
for i.v. dose and 20 μCi/mg at 10 mg/kg for p.o. dose) and [14C]KAF156-2 (specific activity 51 μCi/mg at 3 mg/kg for i.v. dose and 21 μCi/mg at 10 mg/kg for p.o. dose) were dissolved in 5% Solutol HS 15 for dosing. For identification of polar metabolites, two oral doses were prepared as follows: (A) [14C]KAF156-1 (specific activity 3.65 μCi/mg) and [13C6]KAF156-1 were combined to achieve the mass ratio [12C]/[13C6] of 0.9 and (B) [14C]KAF156-2 (specific activity 3.1 μCi/mg) and [13C2]KAF156-2 was combined to achieve the ratio [12C]/[13C6] of 0.9. Both doses were prepared in 5% Solutol HS 15 for oral dosing at 10 mg/kg.

Each rat received an i.v. bolus injection via the jugular vein cannula. Oral dose was administered by gavage in rats.

**Blood Collection**

All rats were housed individually in Culex® metabolism cages to enable automated blood sampling on the day of the study. Blood samples (200 μL) were collected from the carotid artery of rats at selected time intervals. Saline (200 μL) was automatically injected after sample was collected to clear the cannula and replace the volume of blood samples. The total blood volume collected did not exceed 1% of the body weights of rats.

**Urine and feces collection**

Urine and feces were collected daily from each of the animals for 7 days. Up to 3 days the urine collection tubes were cooled with ice. After the final collection, each cage was rinsed with water followed by 50% methanol. The cage wash was assayed for radioactivity. Urine and feces samples were stored at -20 °C until analysis.
Sample preparation

Plasma was obtained by centrifugation of blood samples at 4°C (2000 x g) for 10 min. An aliquot of each blood sample was used for radioactivity analysis. An aliquot of plasma sample was counted directly for radioactivity. The remaining plasma samples were stored at -20 °C until analysis.

Plasma for the quantification of KAF156

Blank plasma and study samples were thawed at room temperature. Calibration standards, control blanks, and quality control (QC) samples were prepared on the day of analysis by adding appropriate standard or QC (25 µL) spiking solution to 475 µL of blank plasma. An aliquot (20 µL) of study samples, blanks, standards or QC samples was transferred to the designated well of a 1 mL round bottom 96-well plate (Analytical sales and services, Pompton plains, NJ), followed by the addition of the internal standard ([13C6]KAF156; 25 µL, 500 ng/mL) and acetonitrile (200 µL) for protein precipitation. Samples were mixed for 5 min and centrifuged at 2500 rpm for 15 min at 25 ºC. The filtrate was evaporated to dryness at ~45°C under a stream of nitrogen (TurboVap LV; Zymark Corp., Taunton, MA). The residues were reconstituted with 300 µL of acetonitrile:water:formic acid (10:90:0.1, v/v/v). An aliquot (10 µL) was analyzed for KAF156 and [13C6]KAF156-1 by LC-MS/MS.

Plasma for metabolic profiling of KAF156

All plasma samples were thawed at room temperature and aliquots (150 µL) were pooled from each animal at each time point. Each pool was diluted with 250 µL water and extracted with 2 mL of acetonitrile:methanol:acetic acid (50:50:0.1, v/v/v). The samples were vortex-mixed followed by centrifugation. The supernatants were evaporated to near dryness under a stream of
nitrogen. The residues were reconstituted with 100 µL of acetonitrile:deionized water (50:50; v/v) and an aliquot was analyzed by LC-MS/MS.

**Urine for metabolic profiling of [14C]KAF156-1 and [14C]KAF156-2**

Urine pools (10-20% by volume) were prepared with samples collected from rats during 0-24 or 0-72 h postdose. The selected time interval represented >91-95% of the total urinary excretion of radioactivity from rats by either dosing route. The pooled samples were centrifuged at 3,500 rpm for 10 min, and aliquots of the resulting supernatant were analyzed by LC-MS/MS.

**Feces for metabolic profiling of [14C]KAF156-1 and [14C]KAF156-2**

Rat feces were collected in 24 h intervals for 7 days. Fecal samples from each rat from each collection interval were homogenized with 2 x water separately. Fecal homogenates, representing ~5-10% of total weight, were pooled from three rats and from 0-24 h and 24-48 h intervals. The selected time interval represented >93% of the total radioactivity excreted in rat feces by either i.v. or p.o. dosing route. The resulting fecal pools were extracted three times with 3 volumes of acetonitrile:methanol:acetic acid (50:50:0.1, v/v/v). After centrifugation at 3,500 x rpm for 10 min, the supernatants were combined and concentrated under a stream of nitrogen. Residues were reconstituted with acetonitrile:deionized water (50/50, v/v) and analyzed by LC-MS/MS. The excretion recoveries of radioactivity from rat feces were ~68-78% (i.v.) and ~69-77% (p.o.), respectively.

**Sample Analysis**

**Determination of radioactivity**

The radioactivity of all samples was determined by liquid scintillation counting (LSC). For quench correction an external standard ratio method was used. Quench correction curves were...
established by means of sealed standards. An aliquot of plasma, urine samples and cage wash were counted directly for radioactivity.

Solvable™ (500 μL) was added to each blood sample and incubated in a shaking water bath at 50°C for 2 h. After incubation, 50 μL of 100 mM EDTA as an anti-foaming agent and 200 μL of 30% hydrogen peroxide were added to decolorize the samples. The sample vials were loosely capped and returned to the water bath for 3 h. Thereafter, 10 mL of Formula 989 scintillation cocktail was added and the samples were placed in the dark overnight to reduce chemiluminescence prior to counting for radioactivity.

Fecal samples from animals were homogenized with 2 or 3 volume of water. Duplicate samples (~100 mg) of the slurry were weighed into scintillation vials and processed as described above for blood samples prior to radioactivity determination. The remaining fecal homogenate was stored frozen at -20°C until LC-MS/MS analysis.

**Quantification of KAF156 by LC-MS/MS**

Samples were analyzed on an LC-MS/MS system consisting of a Shimadzu HPLC System and Sciex API5000 mass spectrometer using Analyst software version 1.4.2 (Foster City, CA, USA). The mass spectrometer was operated in the positive ion mode, using turbo spray ionization, with a source temperature of 500 °C. Chromatographic separation was carried out on a Zorbax SB-C8 50 x 4.6 mm column at 40 °C. KAF156 and the internal standard ([13C6]KAF156-1, Figure 1) were eluted using a gradient method with a mobile phase consisting of A: 10 mM ammonium acetate in water containing 0.03% trifluoracetic acid; and B: 10 mM ammonium acetate in methanol containing 0.03% trifluoracetic acid. The gradient was 30%B for 0.01 min; increased to 95%B from 0.01 to 1 min; followed by a 1.2 min hold at 95%B. The flow rate was 0.6
mL/min. The multiple reaction monitoring (MRM) transitions for KAF156 and [1$^{13}$C$_6$]KAF156-1 were m/z 412.4 to m/z 312.1, and m/z 418.5 to m/z 318.1, respectively.

Calibration curves were generated by plotting the respective peak area ratios (y) of KAF156 to the internal standard versus the concentrations (x) of the calibration standards using weighted 1/x$^2$ quadratic least-squares regression. The quantification was performed using Analyst software and Watson LIMS version 7.2.0.01. Concentrations in QC and study samples were calculated from the resulting peak area ratios and interpolation from the regression equations of the calibration curves. The lower limit of quantification was 1.0 ng/mL.

**Metabolic profiling by LC-MS/MS**

Metabolic profiling was performed on a Waters Acquity UPLC System (Waters Corp., Milford, MA), equipped with an autosampler and a quaternary pump, and an on-line radioactivity monitor (β-RAM) or a fraction collector. Two UPLC methods were developed for the separation of KAF156 and metabolites.

**Method A:** The separation of metabolites was carried out on a Zorbax SB-C18 column (150 x 3.0 mm, 3.5 μm) using a linear gradient with a mobile phase consisting of A: 5 mM ammonium formate containing 0.1% formic acid; and B: acetonitrile containing 0.1% formic acid. The gradient was 2%B for 3 min; increased to 25%B from 3 to 32 min; increased to 60%B from 32 to 45 min; increased to 95%B from 45 to 52 min; hold at 95%B from 52 to 60 min. The flow rate was 0.7 mL/min.

**Method B:** The separation of polar metabolites was carried out on a UPLC HSS T3 column (150 x 3.0 mm, 1.8 μm) using a linear gradient with a mobile phase consisting of A: 5 mM ammonium formate containing 0.1% formic acid; and B: acetonitrile containing 0.1% formic acid.
acid. The gradient was 2%B for 8 min; increased to 25%B from 8 to 18 min; increased to 60%B from 18 to 34 min; increased to 95%B from 34 to 38 min; hold at 95%B from 38 to 40 min. The flow rate was 0.5 mL/min.

The HPLC column eluent was split 1:4 (MS/fraction collector or MS/β-RAM). The eluent from the fraction collector was mixed with methanol (0.5 mL/min) and collected directly into 96-Deepwell LumaPlates coated with solid scintillant at 0.15 min/well using a fraction collector. The plates were dried at 40 °C under a stream of nitrogen. The plates were counted for 10-15 min/well in a TopCount Model NXT radioactivity detector (Perkin-Elmer Life Sciences). Online monitoring with β-RAM employed a 250 µL liquid cell and eluent was mixed with 1.4 mL/min IN-Flow 2:1 (IN/US Systems, Tampa, FL) liquid scintillant. The resulting data were processed using the Laura™ Data System (LabLogic, Inc., ver. 4.0). All quantification was based on the radioactivity associated with the radiochromatographic peaks.

**LC-MS instrumentation and operating conditions**

The structural characterization of metabolites was carried out using the above UPLC method coupled to a two-channel Z-spray (LockSpray™) Waters Synapt G1 or G2 quadrupole time-of-flight mass spectrometer (Manchester, UK). The Q-TOF Synapt was operated in V-mode with a typical resolving power of at least 10,000. Qualitative analyses were carried out using electrospray ionization (ESI) in the positive or negative ion mode using a lock spray source. Leucine enkephalin was used as the mass reference standard for exact mass measurements and was delivered via the second spray channel at a flow rate of 5-10 µL/min.

Accurate mass LC/MS data were collected in an alternating low energy (MS) and elevated energy (MS<sup>E</sup>) mode of acquisition. In low energy MS mode, data was collected at consistent
collision energy of 12 eV. In elevated MS\textsuperscript{E} mode, collision energy was ramped from 15 to 30 eV during data collection cycle.

Metabolites were characterized by TOF MS full scan and product ion scans. Product ion scans were obtained either from dedicated TOF MS/MS experiments or the MS\textsuperscript{E} approach. With TOF MS/MS experiments, the trapping collision energy was ramped from 15 to 20 eV, while the transferred collision energy was set at 6 eV. In the MS\textsuperscript{E} approach, the data were acquired in parallel utilizing alternating low and elevated collision energies. Argon was used as the collision gas for both product ion scanning techniques. Acquiring data with the MS\textsuperscript{E} approach provided for collection of intact precursor ions and fragment ion information.

**NMR analyses of polar metabolites (M7, M10.1 and M12)**

Detailed description for the synthesis of 2-(4-fluorophenyl)-2-oxoacetic acid (M7) and the isolation of polar metabolites from rat urine can be found in Supplemental Methods. \textsuperscript{1}H spectra were acquired for enriched M7, M10.1 and M12 from urine samples as well as 2 reference compounds (4-fluoromandelic acid and 2-(4-fluorophenyl)-2-oxoacetic acid; \textasciitilde100 \mu g). All samples were dissolved in acetonitrile-d\textsubscript{3}.

NMR spectra were acquired on a Bruker UltraShield 600 MHz/54 mm spectrometer equipped with a 5 mm CP TXI 600S3 H-C/N-D-05 Z Cryoprobe. For the double quantum filter correlation spectroscopy (DQF-COSY) spectrum, the 90\degree pulse (P1) was calibrated at a \textsuperscript{1}H transmitter power of 0.2 dB, and the following acquisition parameters were used: acquisition time = 0.75 s, complex increments = 1024, and number of scans = 32. Spectra were processed in MestReNova. DQF-COSY spectra were processed using 8k (f2) by 2k (f1) zero filling. A sine squared window function was applied in both the t1 and t2 dimensions. Detailed description for
the NMR analyses of three polar metabolites from rat urine can be found in Supplemental Methods.

Data Processing

Quantification of KAF156 and metabolites by radiometry

KAF156 and metabolites were quantified in the extracts by radiochromatography. Peaks were selected visually from the radiochromatogram, and their corresponding areas were determined via peak integration (LAURA™).

The percent of radioactivity (PRA) in a particular peak, Z, was calculated as following:

\[
\text{% PRA in } Z = \frac{\text{DPM in peak } Z}{\text{total DPM in all integrated peaks}} \times 100
\]

The concentration or amount of each component was calculated as \%PRA (as a fraction) multiplied by the total concentration (ngEq/mL) or percent of dose in the excreta.

Pharmacokinetic parameters

The pharmacokinetic parameters were calculated using actual recorded sampling times and non-compartmental method(s) with Phoenix (WinNonlin Version 6.2, Pharsight, Certara L.P., USA). Concentrations below the lower limit of quantification (LLOQ) were treated as zero for PK parameter calculations. The linear trapezoidal rule was used for AUC calculation. Regression analysis of the terminal plasma elimination phase for the determination of t\(_{1/2}\) included at least 3 data points after C\(_{max}\). If the adjusted R\(^2\) value of the regression analysis of the terminal phase was less than 0.75, no values were reported for t\(_{1/2}\), AUC\(_{inf}\), V\(_z\)/F and CL/F.
Results

Mass balance and pharmacokinetics of KAF156 in rats

Following *i.v.* or *p.o.* dosing of $[^{14}C]KAF156-1$ or $[^{14}C]KAF156-2$ (Figure 1), mass balance was achieved in rats, with 93-118% of the administered radioactivity dose being recovered in excreta. Higher than 100% of radioactivity recovered in excreta was considered within experimental errors (e.g. pipetting, weighing, and counting etc.). Two tracers ($[^{14}C]KAF156-1$ and $[^{14}C]KAF156-2$ with different $^{14}$C labeling positions) were used in mass balance studies. Following *i.v.* or *p.o.* dosing of $[^{14}C]KAF156-1$, excretion of radioactivity was about equal (~40-56% in urine and ~61-63% in feces). However, following *i.v.* or *p.o.* dosing of $[^{14}C]KAF156-2$, radioactivity was primarily excreted into feces (~23% in urine and ~68-75% in feces).

Following *i.v.* dosing, KAF156 had a moderate terminal half-life ($t_{1/2}$; 6.6 h), high plasma clearance (CL; 5.4 L/h/kg) and large volume of distribution at steady state ($V_{ss}$; 29.5 L/kg). Following *p.o.* dosing, KAF156 absorption rate was moderate with $C_{max}$ of 139 ng/mL observed at 2 h ($t_{max}$). The extent of oral absorption was at least 55%, based on the ratio of the dose-normalized total radioactivity AUC for plasma obtained from *p.o.* vs. *i.v.* dosed rats (data not shown). The estimated oral bioavailability was ~48%, indicating minimal first-pass effect in rats. Detailed summary tables of mass balance and PK parameters can be found in the Supplemental Table S1 and Table S2.

Metabolite profiling of $[^{14}C]KAF156-1$ or $[^{14}C]KAF156-2$ in rat plasma

Following *i.v.* dosing of $[^{14}C]KAF156-1$ or $[^{14}C]KAF156-2$, the prominent radiolabeled components in plasma were KAF156 and three oxidative metabolites (M31, M35.8 and M37),
each accounting for ~12-35% of the total radioactivity AUC$_{0-8h}$. Nomenclature of metabolites was based on their HPLC elution time in the study in which they were first identified. Detailed graphic presentation can be found in the Supplemental Figure S1 and Figure S2.

**Metabolite profiling of $[^{14}C]KAF156$-1 in rat feces**

KAF156 was well absorbed and extensively metabolized in rats such that unchanged KAF156 in feces accounted for ~8-21% of the dose by either i.v. or p.o. dosing route (Figure 2, panel A). Several minor metabolites (M19, M27, M31, M33, M35, M35.8, M37, M37.7, and M43) were identified in rat feces, each accounting for ~2-10% of the dose by either dosing route.

**Characterization of metabolites of $[^{14}C]KAF156$-1 in rat feces**

The structures of the metabolites were proposed based on their elemental composition derived from accurate mass measurements (<3-5 ppm), fragment ions in their data dependent MS$^2$ and MS$^3$ mass spectra. Elemental formula and diagnostic fragmentation ions of KAF156 and metabolites are summarized in Table 1.

KAF156 ([MH]$^+$=412) produced fragments at m/z 312 (loss of ethyl amino acetamide), 245 (loss of HCN from fluorophenyl imidazole amine), 101 (ethyl amino acetamide) and 124 (fluorobenzylideneamine) when analyzed in positive ion mode. Detailed product ion spectra of KAF156 can be found in the Supplemental Figure S3.

**Metabolite profiling of $[^{14}C]KAF156$-1 in rat urine**

A representative radiochromatogram shows the metabolic profiles in urine after an oral dose of $[^{14}C]KAF156$-1 to rats (Figure 2, panel B). KAF156 and six minor metabolites (M31, M35, M35.8, M37, M37.7, and M43) were identified in rat urine. Additionally, four relatively polar metabolites (M3, M5, M10 and M11) were detected by radiochromatography, together accounting for ~35% of the i.v. dose and ~23% of the p.o. dose. Their structures were not
identified due to their poor ionization efficiency under either positive or negative ion mode, their suspected low molecular weights, their relatively short UPLC elution times (~3-11 min) and endogenous urine matrix background. A new UPLC method was developed in order to extend the UPLC elution times of the polar metabolites (~7-18 min), as described as method B in Material and Methods section (graphic presentation can be found in the Supplemental Figure S4).

**Characterization of polar metabolites of \([^{14}\text{C}]\text{KAF156-1}\) in rat urine**

To facilitate the identification of polar metabolites, a mixture of \([^{14}\text{C}]\text{KAF156-1}\) (specific activity 3.65 µCi/mg) and \([^{13}\text{C}_6]\text{KAF156-1}\) was dosed orally to rats. Using the dual labeling approach, three polar metabolites (M3, M10 and M11) were identified by LC-MS/MS analysis using defined mass filters and analyzed under negative ion mode.

As shown in Figure 3 panel A, M3 ([M-H] =206) was assigned as an O-sulfonate conjugate of hydroxylated fluoroaniline. The product ion spectrum showed the characteristic fragments \(m/z\) 126 (loss of SO\(_3\)) and 106 (loss of HF from \(m/z\) 126). As expected, \([^{13}\text{C}_6]\)M3 ([M-H] =212, \(^{13}\text{C}\) isotope ion) generated corresponding fragments at \(m/z\) 132 and 112 (Figure 3, panel B). Using the same isotopic filtering approach, two polar metabolites (M10 and M11) and one less polar metabolite (M43) were identified and their fragment ions are summarized in Table 1. Detailed product ion spectra of M43 can be found in the Supplemental Figure S5.

However, M5 remained unidentified when the mass filters were set at isotopic mass ratio of 0.9 and mass difference at 6.0202 Dalton. Only when the isotopic mass ratio of 0.9 was removed from the mass filter, M5 ([M-H] =230) was detected with mass difference at 6.0202 Dalton. M5 was assigned to be an O-sulfonate conjugate of acetylated and hydroxylated aniline. Interestingly, M5 has lost fluorine vs. other polar metabolites (M3, M10 and M11). Presumably, oxidative defluorination at fluoroaniline has occurred to form M5. The product ion spectrum showed
fragments at \( m/z \) 150 (loss of SO\(_3\)) and 107 (loss of acetyl group from \( m/z \) 150) (Figure 4, panel A). Similarly, \([^{13}C_6]M5\) ([M-H]\( =\)236, \(^{13}\)C isotope ion) generated corresponding fragments at \( m/z \) 156 and 113 (Figure 4, panel B).

As shown in Figure 4 panel C, the ratio of \([^{12}C]/[^{13}C_6]\) changed from 0.9 to ~2, indicating that this metabolite had lost fluorine and co-eluted with an endogenous substance with the same molecular ion of \( m/z \) at 230. Indeed, an endogenous substance with [M-H]\( -\) at \( m/z \) 230 was detected in urine from untreated rat (Figure 5, panel B), which co-eluted with M5 in the UPLC system used in the study (Figure 5, panel C).

**Metabolite profiling of \([^{14}C]KAF156-2\) in rat feces**

To identify any putative metabolite which had lost radiolabeling using \([^{14}C]KAF156-1\), another tracer, \([^{14}C]KAF156-2\) (Figure 1), was synthesized for an additional rat ADME study. Consistent with findings from \([^{14}C]KAF156-1\), KAF156 was well absorbed and extensively metabolized in rats such that unchanged KAF156 in feces accounted for ~8-25% of the dose by either i.v. or p.o. dosing route (Figure 6, panel A). Several metabolites (M19, M27, M33, M36, and M43) were identified in rat feces, each accounting for ~5-13% of the i.v. or p.o. dose. Several minor metabolites (M28, M31, M35, M35.8, M37, M37.7), each accounting for < 3% of the i.v. or p.o. dose, were identified in rat feces. Elemental formula and diagnostic fragmentation ions of KAF156 and metabolites are summarized in Table 1.

**Metabolite profiling of \([^{14}C]KAF156-2\) in rat urine**

A representative radiochromatogram shows the metabolic profiles in urine after an oral dose of KAF156 to rats (Figure 6, panel B). KAF156 and several minor metabolites (M19, M24, M31, M33, M35, M35.8, M36, M37, and M43) were identified in rat urine. However, three relatively polar metabolites (M7, M10.1 and M12), accounting for ~13-14% of the dose by either i.v. or p.o.
dosing route, remained unidentified due to their low ionization efficiency under positive or negative ion mode and substantial urine matrix background. Four previously identified polar metabolites (M3, M5, M10 and M11) were detected by LC-MS/MS and the absence of the $^{14}$C radiolabel in these chemical species precluded their quantification via radiochromatography in this study.

**Characterization of polar metabolites of $[^{14}\text{C}]$KAF156-2 in rat urine**

Using the same dual labeling approach, a mixture of $[^{14}\text{C}]$KAF156-2 (specific activity 3.1 µCi/mg) and $[^{13}\text{C}_2]$KAF156-2 with the ratio of $[^{12}\text{C}]/[^{13}\text{C}_2]$ as 0.9 was dosed orally to rats. Using the isotope mass ratio of 0.9 and the mass difference of 2.006 Dalton as mass filters, two polar metabolites (M7 and M10.1) were identified using LC-MS/MS analysis under negative ion mode. As shown in Figure 7, the metabolite M10.1 ([M-H]$^- = 169$) was assigned as 4-fluoromandelic acid. The product ion spectrum showed characteristic fragments $m/z$ 125 (loss of CO$_2$) and 95 (loss of CH$_2$O from $m/z$ 125). As expected, $[^{13}\text{C}_2]$M10.1 ([M-H]$^- = 171$, $^{13}$C isotope ion) generated corresponding fragments at $m/z$ 127 and 95. Apparently, the fragment ion at $m/z$ 95 was the same for both $[^{12}\text{C}]$ and $[^{13}\text{C}_2]$ molecules since the fragment ion of $m/z$ at 95 excluded two stable isotope labeled carbon atoms. Using the same approach, M7 was identified as the corresponding fluorophenyl oxoacetic acid. The fragment ions of these polar metabolites are summarized in Table 1.

However, the metabolite M12 remained unidentified when the mass filters were set at isotope mass ratio of 0.9 and mass difference at 2.002 Dalton. Presumably one of the two stable isotope labeled carbon atoms was lost during biotransformation and the mass difference was no longer 2.002 Dalton (see below NMR analysis and Figure 8).

**Structural elucidation of polar metabolites by NMR**
4-fluoromandelic acid was purchased from Sigma Aldrich and 2-(4-fluorophenyl)-2-oxoacetic acid was synthesized according to the published procedure (Lee and Chen, 1991). The metabolites M7, M10.1 and M12 were isolated from rat urine and their structures were explored using NMR analyses via comparison with the two reference compounds of 4-fluoromandelic acid and 2-(4-fluorophenyl)-2-oxoacetic acid (FPOAA).

DQF-COSY spectra acquired for the enriched M7-containing urine samples were compared to authentic FPOAA. Additionally, DQF-COSY spectra for the enriched M10.1-containing urine samples were compared to the 4-fluoromandelic acid standard. For both M7 and M10.1 the spectral data matched their corresponding authentic standards as assessed by comparison of chemical shifts and coupling patterns. These NMR data supported the proposed structures based on the initial mass spectrometric analysis of the polar metabolites M7 and M10.1.

The $^1$H spectrum acquired for the M12-enriched NMR sample showed two peaks shifted downfield that integrate with whole-number ratios relative to each other (7.93 and 8.66 ppm; relative integration, 2:1). The chemical shift and relative integration of the signal at 8.66 ppm suggested that this peak represents an amide proton. A DQF-COSY spectrum acquired for the sample revealed that the putative amide proton couples to a methylene at 3.82 ppm. Additionally, the DQF-COSY coupling patterns observed for the aromatic protons at 7.93 ppm were indicative of an aryl group with a fluorine atom substituted at the para position. Further structural analysis via the acquisition of a ROESY spectrum, an experiment provides through space $^1$H, $^1$H-coupling information (see supplementary data for acquisition parameters), demonstrated that the amide proton is proximal to the aromatic protons observed at 7.93 ppm. The chemical shift and position of the methylene, distal to the aromatic ring, was consistent with it being positioned between the amide nitrogen and a carboxylic acid group. This conclusion was supported by mass
spectrometric analysis (Figure 8) and comparison of observed NMR chemical shifts to those reported for 4-fluoro-hippuric acid (Chaves et al., 2010).

Detailed description of the FPOAA synthesis and NMR analyses can be found in the Supplemental Methods, Results and supplemental Figure S6 to Figure S13.

**In vitro metabolism of KAF156 in rat and human hepatocytes**

$[^{14}C]KAF156-1$ (2.5 and 12.5 $\mu$M) was incubated in freshly prepared hepatocyte suspensions for 24 h. The prominent metabolites were M37.7, M19, M27, and M43 in rat hepatocytes; M36, M37.7, and M43 in human hepatocytes, respectively. However, no polar metabolites were generated from hepatocytes even though M43 was a prominent metabolite *in vitro* (graphic presentation can be found in the supplemental Figure S14).

**Proposed metabolite pathways of $[^{14}C]KAF156$ in rats**

Metabolic pathways of KAF156 in rats are summarized in Figure 9. KAF156 was well absorbed and extensively metabolized in rat and unchanged KAF156 only accounted for ~8-25% of the dose by either dosing route. Briefly, KAF156 underwent oxygenation (M31 and M35.8), oxidative defluorination (M19), oxidative deaminantion (M37), combination of oxidative deamination and reduction (M37.7), hydroxylation and ring opening (M24), acetylation (M36), hydrolytic cleavage leading to the imidazole ring opening (M43). Combination of the above reactions and O-sulfonation led to the formation of several down-stream less polar metabolites (M27, M28, M35 and M33) and polar metabolites (M3, M5, M7, M10, M10.1, M11 and M12).
Discussion

KAF156 is an antimalarial agent, which was designed to eradicate both blood-stage and liver-stage malaria parasites, providing a potentially new treatment for malaria prophylaxis (Kuhen et al., 2014; Diagana TT, 2015). To facilitate the understanding of metabolism and disposition of KAF156 in humans, ADME studies in rats and in vitro across species metabolism studies were conducted.

Following i.v. or p.o. dosing of [14C]KAF156-1, mass balance was achieved in rats. The radioactivity was excreted equally via urinary and fecal pathways. KAF156 showed high clearance, large volume of distribution and long terminal half-life in rats. Following p.o. dosing, KAF156 was well absorbed and extensively metabolized in rats such that unchanged KAF156 accounted for only ~8-21% of the dose in feces by either dosing route. The prominent radioactive components in rat plasma were KAF156 and three oxidative metabolites (M31, M35.8 and M37). Several metabolites were identified in urine and feces by LC-MS/MS analysis. However, four prominent polar metabolites, accounting for ~23-35% of the dose by either dosing route were not identified in rat urine due to their low ionization efficiency under either positive or negative ion mode and the endogenous urine matrix background. To facilitate the structural characterization of polar metabolites in rat urine, we developed a new UPLC method which prolonged the retention times of these polar metabolites (Godejohann, 2007; Gray et al., 2011; Heaton et al., 2012; Liu et al., 2010). In addition, we purchased two commercially available putative metabolites (fluoroaniline and hydroxyphenylacetamide) and established their poor ionization efficiency under either positive or negative ion mode.
We decided to utilize the mass filter feature in the accurate mass spectrometer to accelerate the identification of polar metabolites (Ma et al., 2006; Zhang and Mitra, 2013). We designed an oral dosing solution as a mixture of $[^{14}\text{C}]$KAF156-1 (specific activity 3.65 µCi/mg) and $[^{13}\text{C}_6]$KAF156-1. At this stage of drug development, $[^{13}\text{C}_6]$KAF156-1 was available and used as the internal standard for the quantification of KAF156 in toxicology studies, therefore our strategy does not require extra research efforts and resources.

Theoretically, a mixture of $[^{12}\text{C}]$KAF156 and $[^{13}\text{C}_6]$KAF156-1 with the 0.9 mass ratio and 6.0202 mass difference would provide the same information in terms of mass filter application in accurate mass spectrometry. However, in our dual labeling approach, we strategically added trace amount of $[^{14}\text{C}]$KAF156-1 to allow identification of any putative metabolite which no longer satisfied either or both criteria (i.e. mass ratio or mass difference) of a defined mass filter. As described below, we indeed identified two metabolites (M5 and M12) which would have been missed without the addition of radiolabeled tracer in the oral dose.

As expected, three polar metabolites (M3, M10 and M11) and one less polar metabolite (M43) of KAF156 were easily identified in rat urine based on the detection of isotopic pairs of molecular ions with the expected mass ratio and mass difference. Nevertheless, M5 was not identified until the criteria of mass ratio of 0.9 was removed from the mass filter. It turned out that M5 had lost fluorine and co-eluted with an endogenous substance with the identical molecular ion $\text{[M-H]}^-$ of $m/z$ at 230, resulting in the change of mass response ratio of $[^{12}\text{C}]/[^{13}\text{C}_6]$ from 0.9 to ~2. Interestingly, M5 was the only polar metabolite which had lost fluorine, presumably via oxidative defluorination of the fluoroaniline ring, and shared the same elemental composition as an endogenous substance. This conclusion was derived based on the detection of the endogenous substance $\text{[M-H]}^-$ of $m/z$ at 230 in urine from control rats without any treatment.
Concurrently M43, an imidazole ring-opened metabolite, was identified using this dual labeling approach under negative ion mode (Supplemental Figure S5). Apparently, M43 was derived via hydrolytic cleavage at the imidazole ring of KAF156, followed by amide hydrolysis to form a putative intermediate (fluoroaniline), which was further hydroxylated, oxidative defluorinated, acetylated or O-sulfonated to generate above four polar metabolites (M3, M5, M10, and M11).

Consistent with the above in vivo findings, M43 was identified to be the major metabolite when $^{14}$C]KAF156-1 was incubated with rat and human hepatocytes. However, none of polar metabolites were detected from any in vitro incubations even though most less polar metabolites identified in vivo were also generated in rat hepatocytes. The limitation of the in vitro system observed for KAF156 is not unusual since the same experiences have been reported in the literature for many drug candidates. Therefore, the characterization of polar metabolites of KAF156 could only be achieved from an in vivo study.

Accordingly, we were concerned that we may miss the identification of putative metabolites derived from hydrolysis of M43, which may have lost the radiolabeling of $^{14}$C]KAF156-1 and stable isotope labeling of $^{13}$C$_6$]KAF156-1 (e.g. metabolites containing fluorophenyl ring). It would be challenging to identify these putative polar metabolites under either positive or negative ion mode without any mass filter.

Subsequently, we initiated synthesis of another tracer ($^{14}$C]KAF156-2) and strategically radiolabeled the carbon in the imidazole ring adjacent to fluorophenyl ring, to allow detection of any putative hydrolysis metabolites of M43. Following i.v. or p.o. dosing of $^{14}$C]KAF156-2, mass balance was achieved in rats. However, another three polar metabolites in rat urine, accounting for ~13-14% of the dose by either dosing route, were detected but could not characterized by LC-MS/MS analysis due to low ionization efficiency.
To enable the identification of polar metabolites using the same dual labeling approach, we considered two strategies for the stable isotope labeling of KAF156: (A) \([^{13}C_6]KAF156-3\) with stable isotope labeling at six carbon atoms of the fluorophenyl ring and (B) \([^{13}C_2]KAF156-2\) with the stable isotope labeling at two adjacent carbon atoms of the imidazole portion of KAF156 (Figure 1). Based on the fact that carbon atom adjacent to fluorophenyl ring was radiolabeled in \([^{14}C]KAF156-2\), we anticipated \([^{13}C_2]KAF156-2\) and \([^{14}C]KAF156-2\) together would provide us with more information regarding any putative metabolism occurring at imidazolopiperazine moiety. We designed the oral dose as a mixture of \([^{14}C]KAF156-2\) (specific activity 3.1 µCi/mg) and \([^{13}C_2]KAF156-2\) with the mass ratio of \([^{12}C]/[^{13}C_2]\) of 0.9 and the mass difference of 2.006.

As expected, two polar metabolites (M7 and M10.1) containing fluorophenyl ring were identified in rat urine using a defined mass filter. However, M12 was detected by radioactivity but was not selected using the above isotopic mass ratio and mass difference as mass filters. Apparently, M12 lost one labeled carbon atom during biotransformation and could no longer be detected using the above mass filters. Therefore, we initiated the isolation of these polar metabolites from rat urine and elucidated the structure of M12 by NMR and LC-MS/MS analyses. M12 was assigned as a glycine conjugate of fluorobenzoic acid, presumably M7 underwent oxidative decarboxylation and followed by glycine conjugation. Retrospectively, M12 could have been easily identified by LC-MS/MS analysis using the dual labeling approach (strategy A). We did not identify any other new metabolites containing portion of imidazolopiperazine using strategy B.

The formation of imidazole ring opened metabolite M43 was further investigated. As mentioned previously, M43 was identified to be the major metabolite when \([^{14}C]KAF156-1\) was incubated
with rat and human hepatocytes. In addition, M43 was detected at low level when incubated in buffer without hepatocytes (pH 7.4) for 24 h. These findings suggest that the hydrolytic cleavage of imidazole ring was catalyzed enzymatically and with some extent of chemical degradation during hepatocyte incubations. However, M43 was not generated when \([^{14}\text{C}]\text{KAF156-1}\) was incubated with all 19 commercially available recombinant CYP enzymes in the presence of NADPH, indicating that this is not CYP450 catalyzed reaction (data not shown). Therefore, a 2-step hydrolytic cleavage mechanism for the formation of M43 from KAF156 is proposed (Figure 10).

Overall, the dual labeling approach proved to be practical and valuable in the elucidation of polar metabolites of KAF156 with low molecular weights and low ionization efficiency by either positive or negative mode. This approach has been shown to be superior to using stable isotope labeling alone in cases where unexpected biotransformations occurred. However, the decisions regarding the positions of stable isotope labeling and radiolabeling require careful consideration and biotransformation insight.
Acknowledgements

The authors thank Dr. Francis Tse for constructive discussions and continued encouragement and support, Professor Phil Huskey (Rutgers University) for constructive discussion of reaction mechanism, Dr. Amy Wu and Mr. Lawrence Jones for the purification and analytical certification of [14C]KAF156, Dr. Tapan Majumdar and Ms. Shari Wu for the quantification of KAF156 in rat plasma.
Authorship Contributions

Participated in study design: Jian, Ray, He, Flarakos, and Huskey

Conducted experiments: Li, Forseth, Zhang

Performed chemical synthesis: Jian, Forseth

Performed data analysis: Li, Forseth, Catoire, Zhang, and Huskey

Wrote or contributed to the writing of manuscript: Huskey, Forseth, and Mangold
References


Zhang Z and Mitra K (2012) Application of mass spectrometry for metabolite identification,
This article has not been copyedited and formatted. The final version may differ from this version.

DMD #72108

Figure Legends

Figure 1 Structure of (A)\textsuperscript{[14C]}KAF156-1, (B)\textsuperscript{[13C\textsubscript{6}]}KAF156-1, (C)\textsuperscript{[14C]}KAF156-2, (D)\textsuperscript{[13C\textsubscript{2}]}KAF156-2, and (E)\textsuperscript{[13C\textsubscript{6}]}KAF156-3

\textsuperscript{[14C]}KAF156-1 was uniformly labeled with \textsuperscript{14C} (n=1-6), as indicated by asterisk, whereas \textsuperscript{[13C\textsubscript{6}]}KAF156-1 and \textsuperscript{[13C\textsubscript{6}]}KAF156-3 were labeled with six \textsuperscript{13C} atoms in the fluoroaniline or fluorophenyl ring, as indicated by double asterisk, respectively.

Figure 2 Representative metabolic profiles in (A) pooled fecal extracts and (B) pooled urine following \textit{p.o.} dosing of \textsuperscript{[14C]}KAF156-1 to rats

Urine and feces samples were collected daily from rats up to 7 days. After homogenization, fecal homogenates were pooled, extracted and analyzed by LC-MS/MS. The HPLC separation of KAF156 and metabolites was performed, as described in \textit{Materials and Methods} (method A).

Figure 3 Negative product ion spectra of M3 from urine following \textit{p.o.} dosing of \textsuperscript{[14C]}KAF156-1 and \textsuperscript{[13C\textsubscript{6}]}KAF156-1 to rats

The oral dose consisted of \textsuperscript{[12C]}KAF156, trace amount of \textsuperscript{[14C]}KAF156-1 and \textsuperscript{[13C\textsubscript{6}]}KAF156-1. The mass ratio of 0.9 and mass difference of 6.0202 Dalton were used as mass filters for the detection of \textsuperscript{12C} and \textsuperscript{13C\textsubscript{6}} molecular ions (e.g. 205.9927 and 212.0129 in panel C). As expected, product ion spectra of M3 showed pairs of fragments with mass difference of 6.0202 Dalton (e.g. 126.0303 and 132.0504 in panels A and B).
Figure 4  Negative product ion spectra of M5 from urine following p.o. dosing of $[^{14}\text{C}]$KAF156-1 and $[^{13}\text{C}_6]$KAF156-1 to rats

The oral dose consisted of $[^{12}\text{C}]$KAF156, trace amount of $[^{14}\text{C}]$KAF156-1 and $[^{13}\text{C}_6]$KAF156-1. As expected, full and product ion spectra of M5 showed isotopic pairs of molecular ions (panel C) and corresponding fragment ions (Panel A and B) with mass ratio of 0.9 and mass difference of 6.0202 Dalton.

Figure 5  Negative product ion spectra of M5 (A) urine from rats dosed orally with $[^{14}\text{C}]$KAF156-1 and $[^{13}\text{C}_6]$KAF156-1, (B) urine from control rats, and (C) mixture of urine from A and B

LC-MS/MS analysis was performed from (A) urine samples from rats orally dosed with $[^{14}\text{C}]$KAF156-1 and $[^{13}\text{C}_6]$KAF156-1 and (B) urine collected from control rats where molecular ion of $m/z$ at 230 was detected. [M-H]$^-$ of $m/z$ at 230 was detected with identical UPLC elution time when above two samples were mixed together (panel C).

Figure 6  Representative metabolic profiles in (A) pooled fecal extracts and (B) pooled urine following oral dosing of $[^{14}\text{C}]$KAF156-2 to rats

Urine and feces samples were collected daily from rats up to 7 days. After homogenization, fecal homogenate were extracted and analyzed by LC-MS/MS. The HPLC separation of KAF156 and metabolites was performed, as described in Materials and Methods.
Figure 7  Negative product ion spectra of M10.1 from urine following *p.o.* dosing of

\([^{14}\text{C}]\text{KAF156-2 and } [^{13}\text{C}_2]\text{KAF156-2 to rats*[1]}

The oral dose consisted of \([^{12}\text{C}]\text{KAF156, trace amount of } [^{14}\text{C}]\text{KAF156-2 and } [^{13}\text{C}_2]\text{KAF156-2}.* The mass response ratio of 0.9 and mass difference of 2.0060 Dalton were used as mass filters for the detection of \(^{12}\text{C}\) and \(^{13}\text{C}_2\) molecular ions (*e.g.* 169.0300 and 171.0381 at panel A). As expected, product ion spectra of M10.1 showed pairs of fragments with mass difference of 2.0060 Dalton (*e.g.* 125.0388 and 127.0745 at panel B).

Figure 8  Negative product ion spectra of M12 from urine following *p.o.* dosing of

\([^{14}\text{C}]\text{KAF156-2 and } [^{13}\text{C}_2]\text{KAF156-2 to rats*[1]}

The oral dose consisted of \([^{12}\text{C}]\text{KAF156, trace amount of } [^{14}\text{C}]\text{KAF156-2 and } [^{13}\text{C}_2]\text{KAF156-2}.* The mass difference of 2.0060 Dalton was lost, presumably M12 had lost one \(^{13}\text{C}\) during biotransformation. Two companion molecular ions (*e.g.* 196.0416 vs. 197.0471) were detected and product ion spectra showed pairs of fragment ions (152.0560 vs. 153.1311).

Figure 9  Proposed metabolic pathways of KAF156 in rats (A) less polar metabolites and (B) polar metabolites

Structures of metabolites were characterized by LC-MS/MS analyses. Positive ion mode was used for the identification of less polar metabolites whereas negative ion mode was used for the identification of polar metabolites except negative ion mode was used for the identification of a less polar metabolite M43. Proposed structures of M7, M10.1 and M12 were further confirmed by NMR analyses.
Figure 10  Proposed mechanism for the formation of M43 from KAF156
Tables

Table 1  
Fragmentation patterns of KAF156 and metabolites

Structural characterization of metabolites was carried out by LC-MS/MS analysis with accurate mass measurements. The proposed structures of the metabolites were based on their elemental composition derived from accurate mass measurements and fragment ions in their data dependent MS² and MS³ mass spectra. Comparison of metabolite fragment ions with those of KAF156 allowed the assignment of regions of biotransformation.

(A) Under positive ion mode

<table>
<thead>
<tr>
<th>Compound</th>
<th>[MH⁺] m/z</th>
<th>Elemental Formula</th>
<th>Diagnostic fragment ions</th>
</tr>
</thead>
<tbody>
<tr>
<td>KAF156</td>
<td>412.1959</td>
<td>C_{22}H_{24}N_{5}OF_{2}</td>
<td>412, 312, 245, 124, 101, 72</td>
</tr>
<tr>
<td>M19</td>
<td>410.2000</td>
<td>C_{22}H_{25}N_{5}O_{2}F</td>
<td>410, 310, 243, 122, 101</td>
</tr>
<tr>
<td>M24</td>
<td>431.1909</td>
<td>C_{22}H_{25}N_{4}O_{3}F_{2}</td>
<td>431, 413, 373, 231</td>
</tr>
<tr>
<td>M27</td>
<td>452.2107</td>
<td>C_{24}H_{27}N_{5}O_{3}F</td>
<td>452, 310, 243, 143, 101</td>
</tr>
<tr>
<td>M28</td>
<td>411.1844</td>
<td>C_{22}H_{24}N_{4}O_{3}F</td>
<td>411, 310, 243, 200, 102</td>
</tr>
<tr>
<td>M31</td>
<td>428.1898</td>
<td>C_{22}H_{24}N_{5}O_{2}F_{2}</td>
<td>428, 410, 371, 312, 307, 207, 168, 123, 111, 95, 70</td>
</tr>
<tr>
<td>M33</td>
<td>383.1693</td>
<td>C_{21}H_{21}N_{4}O_{2}F</td>
<td>383, 355, 339, 312, 245, 124, 122</td>
</tr>
<tr>
<td>M35</td>
<td>444.1847</td>
<td>C_{22}H_{24}N_{5}O_{3}F</td>
<td>444, 426, 383, 369, 329, 312, 290, 286, 245, 193, 141, 123, 98, 70</td>
</tr>
<tr>
<td>M35.8</td>
<td>428.1890</td>
<td>C_{22}H_{24}N_{5}O_{2}F_{2}</td>
<td>428, 410, 371, 331, 314, 288, 245, 220, 177, 141, 124, 98, 70</td>
</tr>
<tr>
<td>M36</td>
<td>454.2061</td>
<td>C_{24}H_{26}N_{5}O_{2}F_{2}</td>
<td>454, 312, 245, 143, 101</td>
</tr>
<tr>
<td>M37</td>
<td>429.1720</td>
<td>C_{22}H_{24}N_{4}O_{3}F_{2}</td>
<td>429, 383, 355, 312, 272, 245, 124, 84</td>
</tr>
<tr>
<td>M37.7</td>
<td>413.1794</td>
<td>C_{22}H_{23}N_{4}O_{3}F_{2}</td>
<td>413, 312, 245, 124, 102</td>
</tr>
</tbody>
</table>

aThe most abundant fragment ions are highlighted in bold

(B) Under negative ion mode
<table>
<thead>
<tr>
<th>Compound</th>
<th>[MH$^+$] m/z</th>
<th>Elemental Formula</th>
<th>Diagnostic fragment ionsa</th>
</tr>
</thead>
<tbody>
<tr>
<td>KAF156</td>
<td>410.1792</td>
<td>C$<em>{22}$H$</em>{22}$N$_5$O$_2$F$_2$</td>
<td>410, 335, <strong>310</strong></td>
</tr>
<tr>
<td>M3</td>
<td>205.9927</td>
<td>C$_6$H$_5$NO$_4$FS</td>
<td><strong>206</strong>, 188, <strong>126</strong>, 106</td>
</tr>
<tr>
<td>M5</td>
<td>230.0126</td>
<td>C$_8$H$_8$NO$_5$S</td>
<td><strong>230</strong>, 213, <strong>150</strong>, <strong>107</strong>, 97</td>
</tr>
<tr>
<td>M7</td>
<td>167.0145</td>
<td>C$_8$H$_4$FO$_3$</td>
<td>167, 139, <strong>95</strong>, 75</td>
</tr>
<tr>
<td>M10</td>
<td>168.0468</td>
<td>C$_8$H$_7$NO$_2$F</td>
<td>168, <strong>126</strong>, 106</td>
</tr>
<tr>
<td>M10.1</td>
<td>169.0309</td>
<td>C$_8$H$_6$FO$_3$</td>
<td><strong>169</strong>, <strong>125</strong>, 95</td>
</tr>
<tr>
<td>M11</td>
<td>248.0030</td>
<td>C$_8$H$_7$NO$_5$FS</td>
<td><strong>248</strong>, <strong>168</strong>, <strong>126</strong>, 97</td>
</tr>
<tr>
<td>M12</td>
<td>196.0415</td>
<td>C$_9$H$_7$FNO$_3$</td>
<td><strong>196</strong>, <strong>153</strong>, 95</td>
</tr>
<tr>
<td>M43</td>
<td>260.0525</td>
<td>C$_{14}$H$_8$NO$_3$F$_2$</td>
<td><strong>260</strong>, 232, <strong>206</strong>, 166, 149, 136, 116, 110, 95</td>
</tr>
</tbody>
</table>

aThe most abundant fragment ions are highlighted in bold
Figure 1
Figure 2

(A)

(B)
Figure 3

![Molecular structure](image)

1. TOF MSMS 205.99ES-1.36e6
2. TOF MSMS 212.01ES-1.73e6
3. TOF MS ES 205.9927ES-1.32e6
Figure 4
Figure 5


(B) KAF156_G2_Polar_54 1172 (11.055) Cm (1168:1172-(1158:1162+1179:1183)) 1: TOF MS ES- 7.64e5

(C) KAF156_G2_Polar_55 1177 (11.081) Cm (1175:1177-(1161:1166+1183:1185)) 1: TOF MS ES- 6.57e5

This article has not been copyedited and formatted. The final version may differ from this version.

DMD Fast Forward. Published on August 2, 2016 as DOI: 10.1124/dmd.116.072108
This article has not been copyedited and formatted. The final version may differ from this version.
Figure 6

(A)

(B)
Figure 7

A. Chemical structure and mass spectrometry data for compound 1.

B. Additional mass spectrometry data for compound 2.
Figure 8

MSMS, KAF156, Rat 1-4 Urine 0-24h, Conc, Negative
KAF156_Ra_Ur_PO_24_9 15 (11.684)

m/z 196 → m/z 152 → m/z 95

m/z 196

196.0416
153.1311
152.0560
95.0327
89.6424
76.0308
154.1343
182.0268
155.1038
197.0471
199.0957
213.9249

7: TOF MSMS 196.04ES-196.0416 2.03e3

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 9

(A)
Figure 10

KAF156

M43